Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.
4.

Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies.

Papakostas GI, Cooper-Kazaz R, Appelhof BC, Posternak MA, Johnson DP, Klibanski A, Lerer B, Fava M.

Int Clin Psychopharmacol. 2009 Jan;24(1):19-25. doi: 10.1097/YIC.0b013e328314dfaf. Review.

PMID:
19092448
6.
7.

Clinical efficacy of reboxetine in major depression.

Schatzberg AF.

J Clin Psychiatry. 2000;61 Suppl 10:31-8. Review.

8.
9.
10.

Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors.

Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M.

Biol Psychiatry. 2006 Dec 15;60(12):1350-5. Epub 2006 Aug 24. Review.

PMID:
16934768
11.

Reboxetine versus fluoxetine: an overview of efficacy and tolerability.

Massana J.

J Clin Psychiatry. 1998;59 Suppl 14:8-10.

12.

Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R.

J Clin Psychiatry. 1999 Jun;60(6):400-6.

PMID:
10401920
13.

Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.

Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M.

J Clin Psychiatry. 2002 Jan;63(1):31-7.

PMID:
11838623
14.

Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.

Machado M, Iskedjian M, Ruiz I, Einarson TR.

Curr Med Res Opin. 2006 Sep;22(9):1825-37.

PMID:
16968586
15.

Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.

Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ.

Int Clin Psychopharmacol. 2003 Sep;18(5):279-84.

PMID:
12920388
16.

Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches.

Papakostas GI, Fava M, Thase ME.

Biol Psychiatry. 2008 Apr 1;63(7):699-704. Epub 2007 Oct 24.

PMID:
17919460
17.

Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis.

Rahimi R, Nikfar S, Abdollahi M.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):118-27. doi: 10.1016/j.pnpbp.2008.10.018. Epub 2008 Nov 12.

PMID:
19028540
18.

The antidepressant efficacy of reboxetine in patients with severe depression.

Montgomery S, Ferguson JM, Schwartz GE.

J Clin Psychopharmacol. 2003 Feb;23(1):45-50.

PMID:
12544375
19.

Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis.

Pjrek E, Konstantinidis A, Assem-Hilger E, Praschak-Rieder N, Willeit M, Kasper S, Winkler D.

J Psychiatr Res. 2009 May;43(8):792-7. doi: 10.1016/j.jpsychires.2008.11.004. Epub 2009 Feb 23.

PMID:
19230909
20.

The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study.

Dannon PN, Iancu I, Grunhaus L.

Hum Psychopharmacol. 2002 Oct;17(7):329-33.

PMID:
12415550

Supplemental Content

Support Center